Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics

This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased biohazard waste. Further, dry powder aerosol vaccine delivery is superior to liquid aerosol delivery in a number of ways, including: 1) no dose reconstitution required; 2) highly thermostable and may not need cold chain storage; 3) costs less to store and transport; 4) improved efficacy through elimination of liquid spray nasal-dripping. This CDC-Creare invention is unique in that it is inexpensive and suitable for single-use applications, such as vaccination. It prevents the dose being deposited within the lower respiratory tract, improving safety. This delivery system has a broad range of potential applications including, but not limited to, childhood vaccination programs, self-administered therapeutics, and emergency biodefense.

Potential Commercial Applications:		Competitive Advantages:
Intranasal delivery of vaccines and therapeutics Childhood vaccination programs, mass immunization campaigns, or response to epidemics		Safe, needle-less delivery Allows self-administration Improved protection via intranasal immunization Decreased biohazard waste Dose reconstitution is not required Highly thermostable and may not need cold chain storage Cost-effective Primate study with a thermostable measles vaccine expected in the next year

Development Stage:

• In vitro data available
• Prototype

Inventors:

Mark Papania (CDC)  ➽ more inventions...

James Barry

Darin Knaus

Edward Moynihan

Eric Friets

Mark Bagley


Intellectual Property:
U.S. Pat: 10,099,024 issued 2018-10-16
PCT Application No. PCT/US2013/047399
US Application No. 14/409,379
US Application No. 16/125,478

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-258-2013-0
Updated: Dec 4, 2013